Influence of BRCA pathogenic variants in the benefit of secondary cytoreductive surgery.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.6076
Abstract: 6076Background: Germline BRCA pathogenic variants are present in 15% to 25% of ovarian carcinoma patients. These tumors are more sensitive to platinum and PARP inhibitor therapy and have a better p... read more here.
Keywords: pathogenic variants; variants benefit; benefit secondary; influence brca ... See more keywords
Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Gynecologic Oncology"
DOI: 10.3802/jgo.2019.30.e116
Abstract: https://ejgo.org Most women with advanced ovarian cancer develop recurrent disease after the firstline therapy, and chemotherapy remains the standard care of women with platinumsensitive recurrent ovarian cancer. The randomized studies (NCT00565851, NCT01166737, NCT01611766) comparing surgery… read more here.
Keywords: benefit secondary; ovarian cancer; recurrent ovarian; cancer ... See more keywords